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Strategies are needed for human immunodeficiency virus type 1 vaccine development that improves the
neutralizing antibody response against primary isolates of the virus. Here we examined recombinant DNA
priming followed by subunit protein boosting as a strategy to generate neutralizing antibodies. Both plasmid-
based and recombinant protein envelope (Env) glycoprotein immunogens were derived from a primary viral
isolate, JR-FL. Serum from rabbits immunized with either gp120 or gp140 DNA vaccines delivered by gene gun
inoculation followed by recombinant gp120 protein boosting was capable of neutralizing JR-FL. Neither the
DNA vaccines alone nor the gp120 protein alone generated a detectable neutralizing antibody response against
this virus. Neutralizing antibody responses using gp120 DNA and gp140 DNA for priming were similar. The
results suggest that Env DNA priming followed by gp120 protein boosting provides an advantage over either
approach alone for generating a detectable neutralizing antibody response against primary isolates that are
not easily neutralized.
Neutralizing antibodies are considered critical immune com-
ponents for effective vaccination against human immunodefi-
ciency virus type 1 (HIV-1) infection and disease (5, 10, 16, 19).
The HIV-1 envelope glycoproteins (Env) are the primary viral
antigens targeted by neutralizing antibodies. However, efforts
to develop an Env-based immunogen that elicits an effective
neutralizing antibody response are hampered by the high mu-
tation rate of the virus in infected individuals (23) and the re-
sulting genetic heterogeneity and structural complexity exhib-
ited by Env (24). Thus, an effective HIV-1 vaccine will need to
target a plethora of genetic and antigenic variants of the virus.
A variety of candidate HIV-1 vaccines have included Env for
the purpose of generating a neutralizing antibody response (8,
14, 20). Among these, DNA vaccines have proven to be poor
inducers of neutralizing antibodies on their own but nonethe-
less prime for a detectable neutralizing antibody response after
Env protein boosting (1, 9, 11, 13, 21, 22). Unfortunately, the
neutralizing antibodies generated in these studies have primar-
ily targeted T-cell-line-adapted strains and a small fraction of
primary isolates of HIV-1 that are unusually sensitive to neu-
tralization. Most primary isolates of HIV-1 are substantially
less sensitive to neutralization and more difficult to target with
vaccines (2–4, 15).
It has not been clear whether the DNA prime and protein
boost strategy affords an advantage over Env protein immuni-
zation alone with respect to the elicitation of a neutralizing
antibody response that targets typical primary HIV-1 isolates
that are not easily neutralized. In this regard, the JR-FL strain
of HIV-1 exhibits such a neutralization phenotype (6) and
therefore represents a relevant viral target upon which differ-
ent vaccine strategies can be evaluated and compared. In the
present study, we investigated the ability of the JR-FL gp120
protein to generate a neutralizing antibody response with and
without prior priming with recombinant DNA vaccines ex-
pressing soluble secreted forms of either JR-FL gp120 or
JR-FL gp140.
Two versions of JR-FL Env DNA vaccines were constructed
by subcloning codon-optimized JR-FL Env gene sequences (7)
into the pJW4303 DNA vaccine vector (12). The gp120 DNA
vaccine codes for the ectodomain of the JR-FL Env protein.
The gp140 DNA vaccine encodes gp120 plus the extracellular
region of gp41, with the cleavage site between gp120 and gp41
left intact. Results of a previous study suggested that both the
gp120 and gp140 forms of Env DNA vaccines were able to
overcome the low immunogenicity of a full-length Env DNA
vaccine, insofar as high-level anti-Env antibody responses were
elicited by the gp120 and gp140 DNA vaccines compared to a
gp160 DNA vaccine (13). The expression of JR-FL gp120 and
gp140 by the DNA vaccines was confirmed by Western blotting
using supernatants from 293T cells transiently transfected with
either of the two DNA plasmids.
In the present study, Env DNA priming followed by gp120
protein boosting was compared to gp120 protein immunization
alone. New Zealand White rabbits received either a gp120
DNA vaccine (RJ001 and RJ002) or a gp140 DNA vaccine
(RJ003 and RJ004) by gene gun inoculation at weeks 0, 4, 8,
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and 12. The DNA dose at each immunization was 36 g. The
recombinant JR-FL gp120 protein consisted of 100 g of
gp120 mixed with incomplete Freund’s adjuvant; the gp120
protein was administered by intramuscular injection at weeks
16 and 20. One control group (rabbits RJ005 and RJ006) was
inoculated with empty DNA vector at weeks 0, 4, 8, and 12
followed by two gp120 protein boosts at weeks 16 and 20. A
second control group (RJ007 to RJ009) was inoculated with
gp120 protein at weeks 2, 4, 8, and 30 (Fig. 1).
JR-FL Env-specific immunoglobulin G (IgG) responses were
examined by enzyme-linked immunosorbent assay (ELISA)
(Fig. 1). Priming with either gp120 DNA or gp140 DNA and
boosting with gp120 protein generated anti-Env antibody re-
sponses higher than those in control animals that either re-
ceived protein alone or were primed with empty DNA vector
and boosted with protein. Little difference was seen in the
magnitude of the response between the gp120 DNA-primed
and gp140 DNA-primed animals. Repeated boosting with ei-
FIG. 1. HIV-1 JR-FL Env-specific IgG responses in New Zealand White rabbits as measured by ELISA. (A) Temporal serum anti-gp120 IgG
responses were monitored for rabbits immunized with either the JR-FL gp120 DNA vaccines (RJ001 and RJ002), the JR-FL gp140 DNA vaccines
(RJ003 and RJ004), or the control vector DNA plasmid (RJ005 and RJ006) followed by gp120 protein boosts. Rabbits in the second control group
(RJ007 to RJ009) received four JR-FL gp120 protein immunizations without a DNA prime. Black arrows indicate the times of DNA immuni-
zations, and open arrows indicate the times of protein immunizations. Equal amounts of the JR-FL gp120 antigens (0.1 g/well) were added to
plates precoated with concanavalin A (5 g/well). Detection of gp120-specific IgG was done as previously reported (13) using biotinylated anti-
rabbit IgG and horseradish peroxidase-conjugated streptavidin (Vector Lab). (B) The end titration titers of the above rabbit sera were determined
when the optical density readings at the highest serum dilution were twofold above the optical density reading of the negative control wells with
the normal rabbit sera. Geometric means of the anti-gp120 IgG titers are shown with standard deviations for sera collected before the start of immu-
nization (Pre-immune), 2 weeks after the fourth DNA immunization (DNA prime), or 2 weeks after one or more protein boosts (as indicated).
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ther protein alone or after empty vector DNA priming was less
effective, in that peak titers of anti-Env IgG were approxi-
mately 1 log lower than the peak titers generated by Env DNA
priming plus protein boosting (Fig. 1B).
The serum samples were next assessed for neutralizing ac-
tivity against the vaccine strain, JR-FL, and a highly neutral-
ization-sensitive R5 strain, SF162 (Fig. 2). Neutralization was
measured as either reductions in p24 Gag antigen synthesis in
peripheral blood mononuclear cells (18) or reductions in Tat-
responsive luciferase reporter gene expression in 5.25.EGFP.
Luc.M7 cells (17). Antibodies capable of neutralizing JR-FL
were detected only in animals that were primed with Env DNA
and boosted with protein. In these animals, sporadic neutral-
ization of JR-FL was detected after DNA priming. Neutraliz-
ing activity was much more consistent after protein boosting, as
detected in both assays. Titers of neutralizing antibodies against
JR-FL were between 1:12 and 1:48 (Fig. 2B). There were no
clear differences in the magnitude of this response in animals
primed with gp120 DNA and those primed with gp140 DNA.
Env DNA alone and gp120 protein alone were both capable
of generating antibodies that neutralized SF162. This response
rose in magnitude after gp120 protein boosting in Env DNA-
primed animals, at which time the titers surpassed those in
animals immunized with empty vector DNA and boosted with
gp120 protein (Fig. 2B). As with JR-FL, no clear difference was
seen between gp120 DNA priming and gp140 DNA priming
FIG. 2. Neutralizing activities of rabbit sera. Neutralization was measured as either reductions in p24 Gag antigen synthesis in peripheral blood
mononuclear cells (A) (18) or reductions in Tat-responsive luciferase reporter gene expression in 5.25.EGFP.Luc.M7 cells (B) (17). The actual
percent reductions of p24 Gag antigen at rabbit serum dilutions of 1:4 or 1:12 were used for panel A. Any reduction of p24 less than 50% is
indicated by . Neutralization titers are the dilution at which relative luminescence units (RLU) were reduced by 50% compared to virus control
wells after subtraction of background RLU (B). Sera collected before the start of immunization (Pre-immune), 2 weeks after the last DNA
immunization (DNA prime), or 2 weeks after one or more protein immunizations (as indicated) were used in both types of neutralization studies.
The starting serum dilution was 1:20 for assay against SF162 and 1:10 for assay against JR-FL. NAb, neutralizing antibody.
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for generating antibodies that neutralize SF162. The differen-
tial neutralization of SF162 and JR-FL suggests that recom-
binant gp120 alone was able to elicit an antibody response
against certain shared determinants but was not effective in
eliciting antibodies recognizing specific antigenic conforma-
tions associated with JR-FL neutralization. It appears that
priming with Env DNA and boosting with gp120 protein was
able to circumvent this problem.
We further studied the breadth of the anti-Env antibody
responses after gp120 protein boosting in Env DNA-primed
rabbits by using highly sensitive surface plasmon resonance
analysis. Biacore chips were coated individually with a panel of
five recombinant gp120 antigens produced from CHO cells.
The rabbit sera showed high specificity against the autologous
JR-FL gp120 antigen, moderate reactivity against gp120 from
primary HIV-1 isolates 92MW959 (subgroup C), 92UG21-9
FIG. 3. Breadth of rabbit anti-gp120 IgG responses in rabbit sera showed positive neutralizing antibody responses against JR-FL. (A) Cross-
reactivity of antibodies specific for HIV-1 gp120s in rabbit sera 2 weeks after the second protein boost was assessed using a Biacore 3000 biosensor.
Each serum sample was diluted 1/100 in HBT-CMD running buffer (HEPES buffer, pH 7.4, 150 mM NaCl, 0.1% Tween 20, 0.5% soluble
carboxymethyl dextran) and passed at a flow rate of 5 l/min for 20 min over surfaces to which the indicated gp120s had been covalently coupled
to a density of approximately 750 relative units (RU). A reference flow cell was coated with alcohol dehydrogenase to approximately the same
density to control for nonspecific surface effects. The response obtained from each sensorgram 5 s prior to the end of the association phase was
determined. The response from preimmune serum of each rabbit was subtracted to control for nonspecific binding of serum proteins to the sensor
surface. (B) The same rabbit serum samples at 2 weeks after the second protein boost were analyzed for neutralizing activities against four primary
HIV-1 isolates (1196, 0692, 6101, and PVO) in addition to the autologous JR-FL strain. All of the viruses were grown in peripheral blood
mononuclear cells, and the assays were conducted in 5.25.EGFP.Luc.M7 cells (17) with rabbit serum at a 1:10 dilution. Neutralizing activities are
presented as the percent reduction of RLU compared to virus control wells after subtraction of background RLU. Preimmune sera for all four
rabbits did not show any positive neutralizing activities (data not shown).
FIG. 4. Avidity of gp120-specific IgG in rabbits that received recombinant gp120 protein antigens with (RJ001 and RJ002) and without (RJ005
and RJ006) gp120 DNA priming. Avidity was measured by NaSCN displacement ELISA (21). Rabbit sera were first added to the ELISA plate
coated with JR-FL gp120 and incubated for 60 min at 23°C. After washing, increasing concentrations of sodium thiocyanate (NaSCN) were added
to the plates for 20 min. After another round of washing, bound antibodies were detected by using the regular ELISA procedure as previously
described (21). Rabbit sera collected 2 weeks after the last DNA immunization (DNA prime) or 2 weeks after one or two protein boosts (as in-
dicated) were used.
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(subgroup A), and 92TH14-12 (subgroup B), and poor reac-
tivity against gp120 from ADA (subgroup B) (Fig. 3A). These
data indicated that serum samples from rabbits immunized
with JR-FL gp120 (delivered by DNA prime and protein boost)
had a preferred reactivity against the autologous JR-FL gp120
antigen.
The same serum samples were tested for neutralizing activity
against additional heterologous strains of HIV-1 to determine
whether there might have been a significant improvement in
breadth (Fig. 3). The most potent neutralizing activity was
detected against SS1196, a strain of virus that is generally more
sensitive to neutralization than JR-FL (D. Montefiori, unpub-
lished observations). Little or no neutralizing activity against
other heterologous primary isolates was detected. This limited
cross-neutralizing activity indicates that additional improve-
ments in immunogen design, such as a polyvalent Env formu-
lation, will be needed to elicit a neutralizing antibody response
of sufficient breadth to benefit a vaccine.
The exact mechanism underlying the advantage of DNA
prime plus protein boost is not clear at this point. Results of a
previous study suggested that antibody maturation through
increased avidity might be responsible for improved neutraliz-
ing activity in rabbits immunized by DNA priming and protein
boosting (21). We therefore examined avidity in the presence
of increasing concentrations of NaSCN. Consistent with pre-
vious results mentioned above, avidity increased more rapidly
after gp120 boosting in gp120 DNA-primed rabbits than in
rabbits that were primed with vector DNA (Fig. 4). However,
our results cannot exclude the possibility that the difference in
avidity is in part due to the duration and/or the number of
immunizations used in this study.
Our results suggest that, in addition to a dose-sparing ben-
efit, the DNA prime and Env protein boost strategy may be
superior to Env protein alone when evaluating candidate HIV-
1 Env vaccines for optimal neutralizing antibody responses.
At this point, we are not aware of any adjuvant that can assist
recombinant gp120 to specifically improve the quality of neu-
tralizing antibody response against more resistant primary
HIV-1 isolates. Therefore, the potential advantage for neutral-
izing antibody responses would add to the value of DNA vac-
cines that also induce HIV-1-specific T-cell responses.
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